Effect of butaclamol, a new neuroleptic, on serotoninergic mechanisms.
Butaclamol (1.0-0.1 mg kg-1, i.p.) and spiroperidol (1-0-0-5 mg kg-1, i.p.) but not (-)-butaclamol (15 mg kg-1, i.p.), blocked the hyperactivity induced in rats by tranylcypromine-L-tryptophan pretreatment. Neither butaclamol nor spiroperidol altered the accumulation of brain 5-HT following parglyine or the decline of brain 5-HT following inhibition with the tryptophan hydroxylase inhibitor alpha-propyldopacetamide thus indicating that butaclamol and spiroperidol do not affect either the synthesis or the turnover of brain 5-HT. It is concluded that the antagonism of the tranylcypromise-L-tryptophan-induced hyperactivity by butaclamol and spiroperidol is due to their blockade of dopaminergic receptors rather than an action on neuronal serotoninergic mechanisms.
D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D001923:Brain Chemistry / Q000187:drug effects; D003986:Dibenzocycloheptenes / Q000494:pharmacology*; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D051381:Rats; D012701:Serotonin / Q000494:pharmacology*; D013134:Spiperone / Q000494:pharmacology; D013268:Stimulation, Chemical; D014191:Tranylcypromine / Q000494:pharmacology*; D014364:Tryptophan / Q000494:pharmacology
D003986:Dibenzocycloheptenes; D012701:Serotonin; D014191:Tranylcypromine; D013134:Spiperone; D014364:Tryptophan